GlassScriptPhysician profile
Lawrence S Mcgee
NPI 1124008644
$10,665.34
in general payments reported to CMS, 2019-2025
32 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,625 · 2020: $1,235 · 2021: $1,902 · 2022: $1,777 · 2023: $1,574 · 2024: $1,490 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,912 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,912.20 |
| Education | $214.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,216.25 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $931.85 | 2020-2024 | Acthar, Terlivaz |
| Akebia Therapeutics INC | $929.96 | 2019-2025 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals LP | $900.79 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $817.66 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $738.76 | 2021-2025 | |
| Travere Therapeutics, INC. | $685.76 | 2022-2025 | |
| Vifor Pharma, INC. | $643.32 | 2019-2025 | Veltassa |
| Glaxosmithkline, LLC. | $578.64 | 2019-2023 | Benlysta, Jesduvroq |
| Horizon Therapeutics Plc | $437.67 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $405.17 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $273.22 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $237.99 | 2022-2025 | Tarpeyo |
| Nuwellis, INC. | $220.31 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $212.42 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $208.71 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $195.05 | 2024-2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $176.28 | 2022-2024 | Purified Cortrophin Gel |
| Novo Nordisk INC | $136.78 | 2023-2025 | Rivfloza, Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $129.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.37 | 2024 | Jardiance |
| Rockwell Medical, INC. | $76.16 | 2020 | |
| Arbor Pharmaceuticals, INC. | $73.80 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $65.37 | 2021-2022 | |
| Lilly USA, LLC | $52.02 | 2024-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $46.70 | 2021 | |
| Scpharmaceuticals INC. | $44.03 | 2025 | |
| Apellis Pharmaceuticals, INC. | $30.25 | 2025 | Empaveli |
| Cormedix INC. | $28.66 | 2024 | Defencath |
| Kyowa Kirin, INC. | $17.44 | 2023 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.